Skip to content
Search

Latest Stories

Opioid overdose: Pharmacy professionals to be able to supply naloxone without a prescription

Opioid overdose: Pharmacy professionals to be able to supply naloxone without a prescription

DHSC also publishes a new 10-year strategic plan to expand and improve the drug and alcohol workforce

The UK government has announced plans to update legislation to enable more services and individuals to provide take-home supplies of naloxone – a life-saving opioid overdose antidote - over the next few weeks.

Naloxone can immediately reverse the effects of an opioid overdose by reversing breathing difficulties. The medicine can be administered by anyone in an emergency. However, current legislation allows only drug and alcohol treatment services to supply it without a prescription to individuals for future use.


The Department of Health and Social Care (DHSC) confirmed on Tuesday (14 May) that more professionals, including nurses, paramedics, police officers, probation officers and pharmacy professionals, will be able to supply the medicine without a prescription to save lives.

Health and Social Care Secretary Victoria Atkins warned that opioid addiction can ruin lives and it accounts for the largest proportion of drug-related deaths across the UK.

“We are working hard to reduce those numbers by expanding access to naloxone to save the lives of the most vulnerable,” she said.

The UK government is aiming to prevent nearly 1,000 drug-related deaths in England by the end of 2025.

The decision to widen access to take-home naloxone follows two government consultations conducted in 2021 and 2024, respectively.

“As a result of the overwhelming support, we are proceeding with the proposed legislative changes during spring 2024,” the government said in its response to the latest consultation, also published on Tuesday.

Additionally, the government has released a new 10-year strategic plan to expand and improve the drug and alcohol treatment and recovery workforce.

Key milestones outlined included recruiting more new and experienced professionals into the sector and developing better training for roles that are presently unregulated, such as drug and alcohol workers.

Developed by the Office for Health Improvement and Disparities (OHID) and NHS England, the new workforce plan builds on the progress of the government’s previous 10-year strategy to combat illicit drug use and reduce drug deaths.

As part of the strategy, an additional £532 million is being invested between 2022 and 2025 to improve the capacity and quality of drug and alcohol treatment. More than 3,900 additional staff have been recruited thus far through this funding.

The Health Secretary noted that the 10-year workforce plan will expand and boost the training of the next generation of drug and alcohol workers to improve services and support people to get their lives back on track.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less